Literature DB >> 24766459

Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice.

Eva Billerbeck1, Rachael N Labitt, Kevin Vega, Natalia Frias-Staheli, Marcus Dorner, Jing W Xiao, Charles M Rice, Alexander Ploss.   

Abstract

Differentiation of CD4(+) T cells into type 1 or type 2 subsets is mediated by the expression of the opposing lineage defining transcription factors T-bet and GATA-3. However, the existence of GATA-3(+) T-bet(+) CD4(+) T cells in mice suggests functional plasticity of these subsets. Little is known about type 1 and type 2 plasticity of human T-cell subsets in vivo. Here, we show that in the xenogeneic environment of humanized mice, which lacks a functional immune-regulatory network, human CD4(+) and, notably, CD8(+) T cells preferentially differentiate into interleukin (IL)-4(+) GATA-3(+) and IL-4(+) interferon-γ(+) GATA-3(+) T-bet(+) subsets. Treatment with recombinant human IL-12 or expansion of IL-12-producing human dendritic cells in vivo reverted this phenotype and led to the down-regulation of GATA-3 expression. These changes also correlated with improved antiviral immune responses in humanized mice. In conclusion, our study shows the capacity of human CD4(+) and CD8(+) T cells for stable co-expression of GATA-3 and T-bet in humanized mice and reveals a critical role for IL-12 in regulating this phenotype.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  T-cell plasticity; humanized mice; interleukin-12

Mesh:

Substances:

Year:  2014        PMID: 24766459      PMCID: PMC4172137          DOI: 10.1111/imm.12304

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Authors:  Michael W Melkus; Jacob D Estes; Angela Padgett-Thomas; Joel Gatlin; Paul W Denton; Florence A Othieno; Anja K Wege; Ashley T Haase; J Victor Garcia
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

3.  Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions.

Authors:  Ahmed N Hegazy; Michael Peine; Caroline Helmstetter; Isabel Panse; Anja Fröhlich; Andreas Bergthaler; Lukas Flatz; Daniel D Pinschewer; Andreas Radbruch; Max Löhning
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

4.  FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.

Authors:  Yitian Ding; Andrew Wilkinson; Adi Idris; Ben Fancke; Meredith O'Keeffe; Dalia Khalil; Xinsheng Ju; Mireille H Lahoud; Irina Caminschi; Ken Shortman; Robyn Rodwell; Slavica Vuckovic; Kristen J Radford
Journal:  J Immunol       Date:  2014-01-22       Impact factor: 5.422

5.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

Authors:  Fumihiko Ishikawa; Masaki Yasukawa; Bonnie Lyons; Shuro Yoshida; Toshihiro Miyamoto; Goichi Yoshimoto; Takeshi Watanabe; Koichi Akashi; Leonard D Shultz; Mine Harada
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

7.  Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice.

Authors:  Qingfeng Chen; Maroun Khoury; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

8.  Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.

Authors:  Michael A Brehm; Amy Cuthbert; Chaoxing Yang; David M Miller; Philip DiIorio; Joseph Laning; Lisa Burzenski; Bruce Gott; Oded Foreman; Anoop Kavirayani; Mary Herlihy; Aldo A Rossini; Leonard D Shultz; Dale L Greiner
Journal:  Clin Immunol       Date:  2010-01-21       Impact factor: 3.969

9.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

Review 10.  How are T(H)1 and T(H)2 effector cells made?

Authors:  Derk Amsen; Charalampos G Spilianakis; Richard A Flavell
Journal:  Curr Opin Immunol       Date:  2009-04-15       Impact factor: 7.486

View more
  15 in total

Review 1.  In-situ tumor vaccination: Bringing the fight to the tumor.

Authors:  Robert H Pierce; Jean S Campbell; Sara I Pai; Joshua D Brody; Holbrook E K Kohrt
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.

Authors:  Yueting Wu; Wentao Deng; Emily Chambers McGinley; David J Klinke
Journal:  Pigment Cell Melanoma Res       Date:  2017-03-07       Impact factor: 4.693

3.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  Modulation of T helper 1 and T helper 2 immune balance in a murine stress model during Chlamydia muridarum genital infection.

Authors:  Tesfaye Belay; Elisha Martin; Gezelle Brown; Raenel Crenshaw; Julia Street; Ashleigh Freeman; Shane Musick; Tyler J Kinder
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

Review 5.  Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study.

Authors:  David J Klinke
Journal:  J Immunother Cancer       Date:  2015-06-16       Impact factor: 13.751

Review 6.  Translating Treg Therapy in Humanized Mice.

Authors:  Susanne A Hahn; Iris Bellinghausen; Bettina Trinschek; Christian Becker
Journal:  Front Immunol       Date:  2015-12-14       Impact factor: 7.561

Review 7.  Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.

Authors:  Maria Moschovi; Maria Adamaki; Spiros A Vlahopoulos
Journal:  Oncol Rev       Date:  2016-06-30

8.  Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.

Authors:  Monica Bartucci; Anna C Ferrari; Isaac Yi Kim; Alexander Ploss; Martin Yarmush; Hatem E Sabaawy
Journal:  Front Cell Dev Biol       Date:  2016-07-11

9.  Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome.

Authors:  Florian Douam; Gabriela Hrebikova; Yentli E Soto Albrecht; Julie Sellau; Yael Sharon; Qiang Ding; Alexander Ploss
Journal:  Nat Commun       Date:  2017-03-14       Impact factor: 14.919

10.  Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.

Authors:  Monica Bartucci; Anna C Ferrari; Isaac Yi Kim; Alexander Ploss; Martin Yarmush; Hatem E Sabaawy
Journal:  Front Cell Dev Biol       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.